240 related articles for article (PubMed ID: 31396084)
1. Nocebo in Biosimilars and Generics in Neurology: A Systematic Review.
Spanou I; Mavridis T; Mitsikostas DD
Front Pharmacol; 2019; 10():809. PubMed ID: 31396084
[No Abstract] [Full Text] [Related]
2. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice.
Mitsikostas DD; Chalarakis NG; Mantonakis LI; Delicha EM; Sfikakis PP
Eur J Neurol; 2012 May; 19(5):672-80. PubMed ID: 21973313
[TBL] [Abstract][Full Text] [Related]
3. Nocebo in Alzheimer's disease; meta-analysis of placebo-controlled clinical trials.
Zis P; Mitsikostas DD
J Neurol Sci; 2015 Aug; 355(1-2):94-100. PubMed ID: 26073486
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of placebo-arm dropouts in osteoporosis randomized-controlled trials and implications for nocebo-associated discontinuation of anti-osteoporotic drugs in clinical practice.
Kravvariti E; Kasdagli MI; Diomatari KM; Mouratidou P; Daskalakis K; Mitsikostas DD; Sfikakis PP; Yavropoulou MP
Osteoporos Int; 2023 Mar; 34(3):585-598. PubMed ID: 36596944
[TBL] [Abstract][Full Text] [Related]
5. The nocebo effect: a clinical challenge in the era of biosimilars.
Pouillon L; Socha M; Demore B; Thilly N; Abitbol V; Danese S; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2018 Sep; 14(9):739-749. PubMed ID: 30118338
[TBL] [Abstract][Full Text] [Related]
6. Nocebo in clinical trials for depression: a meta-analysis.
Mitsikostas DD; Mantonakis L; Chalarakis N
Psychiatry Res; 2014 Jan; 215(1):82-6. PubMed ID: 24210741
[TBL] [Abstract][Full Text] [Related]
7. Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?
D'Amico F; Solitano V; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2021 Jan; 21(1):47-55. PubMed ID: 32857634
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Implications of Nocebo Effects for Biosimilar Therapy.
Colloca L; Panaccione R; Murphy TK
Front Pharmacol; 2019; 10():1372. PubMed ID: 31849647
[TBL] [Abstract][Full Text] [Related]
9. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.
Pouillon L; Danese S; Hart A; Fiorino G; Argollo M; Selmi C; Carlo-Stella C; Loeuille D; Costanzo A; Lopez A; Vegni E; Radice S; Gilardi D; Socha M; Fazio M; González-Lorenzo M; Bonovas S; Magro F; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2019 May; 49(9):1181-1187. PubMed ID: 30932219
[TBL] [Abstract][Full Text] [Related]
10. Nocebo in multiple sclerosis trials: A meta-analysis on oral and newer injectable disease-modifying treatments.
Gklinos P; Papadopoulos D; Mitsikostas DD
Mult Scler Relat Disord; 2019 Nov; 36():101389. PubMed ID: 31525626
[TBL] [Abstract][Full Text] [Related]
11. Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder. A meta-regression analysis.
Meister R; Jansen A; Härter M; Nestoriuc Y; Kriston L
J Affect Disord; 2017 Jun; 215():288-298. PubMed ID: 28363152
[TBL] [Abstract][Full Text] [Related]
12. [Biosimilars and the nocebo effect].
Braun J; Tsiami S; Buehring B; Kiefer D; Andreica I; Baraliakos X; Kiltz U
Z Rheumatol; 2020 Apr; 79(3):267-275. PubMed ID: 31802197
[TBL] [Abstract][Full Text] [Related]
13. The Placebo and Nocebo Responses in Clinical Trials in Inflammatory Bowel Diseases.
Enck P; Klosterhalfen S
Front Pharmacol; 2021; 12():641436. PubMed ID: 33867990
[TBL] [Abstract][Full Text] [Related]
14. Nocebo effect in multiple system atrophy: systematic review and meta-analysis of placebo-controlled clinical trials.
Wang ZX; Zhang NN; Zhao HX; Song J
Neurol Sci; 2022 Feb; 43(2):899-905. PubMed ID: 34973075
[TBL] [Abstract][Full Text] [Related]
15. Placebo and nocebo effects in the neurological practice.
Bittar C; Nascimento OJ
Arq Neuropsiquiatr; 2015 Jan; 73(1):58-63. PubMed ID: 25608129
[TBL] [Abstract][Full Text] [Related]
16. Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis.
Stathis P; Smpiliris M; Konitsiotis S; Mitsikostas DD
Eur J Neurol; 2013 Mar; 20(3):527-533. PubMed ID: 23145482
[TBL] [Abstract][Full Text] [Related]
17. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis.
Häuser W; Sarzi-Puttini P; Tölle TR; Wolfe F
Clin Exp Rheumatol; 2012; 30(6 Suppl 74):78-87. PubMed ID: 23137770
[TBL] [Abstract][Full Text] [Related]
18. The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes.
Chavarria V; Vian J; Pereira C; Data-Franco J; Fernandes BS; Berk M; Dodd S
Clin Ther; 2017 Mar; 39(3):477-486. PubMed ID: 28237673
[TBL] [Abstract][Full Text] [Related]
19. Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: Systematic review and meta-analysis of placebo-controlled clinical trials.
Zis P; Shafiq F; Mitsikostas DD
Seizure; 2017 Feb; 45():95-99. PubMed ID: 27978485
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
